Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
13:26
Two 16-year-old teenagers died after the car they were in caught fire in Suceava County
13:14
Volodymyr Zelenskyy approved the retaliation plan proposed by the Security Service of Ukraine and the Army following the series of massive attacks launched by Russia against Ukrainian cities
13:00
Volodymyr Zelensky accuses Russia of attacking airports in Kyiv and Boryspil ahead of the US envoys’ visit
12:52
Botoşani: A man was detained for 24 hours after shooting a rabbit without having a hunting license
12:42
Aryna Sabalenka complained to the umpire about the smell of marijuana from the stands during her victory at the US Open
See more news